|Idera Pharmaceuticals, Inc.|
167 Sidney Street
United States - Map
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for oncology and rare diseases in the United States. It uses two proprietary drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and third-generation antisense (3GA) technology. The companys lead drug candidate is IMO-8400, which is in Phase I/II clinical trials for the treatment of Waldenströms Macroglobulinemia and diffuse large B-cell lymphoma, as well as in Phase II clinical trial for the treatment of dermatomyositis. Its drug candidates also comprise IMO-9200, a drug candidate in Phase I clinical trial for use in selected autoimmune disease indications; and IMO-2055/IMO-2125 that are in Phase I/II clinical trials for applications as immune therapies for the treatment of cancer. In addition, the company is developing drug candidates to turn off the messenger RNA associated with disease causing genes. It has license and research collaboration agreement with Merck & Co. to research, develop, and commercialize vaccine products containing TLR7, TLR8, and TLR9 agonists in the fields of cancer, infectious diseases, and Alzheimers disease; an agreement with Abbott Molecular Inc. for the development of an in vitro companion diagnostic test; a collaboration and license agreement with GSK to research, develop, and commercialize selected molecules from its 3GA technology for the treatment of selected targets in renal disease. Idera Pharmaceuticals, Inc. was founded in 1989 and is based in Cambridge, Massachusetts.
|Idera Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Apr 1, 2016 is 8. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 10; Compensation: 7.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. Vincent J. Milano ,
Chief Exec. Officer, Pres and Director
|Mr. Louis J. Arcudi III, MBA,
Chief Financial Officer, Sr. VP of Operations, Treasurer and Assistant Sec.
|Mr. Mark J. Casey Esq,
Sr. VP, Gen. Counsel and Sec.
|Mr. Robert Clayton Fletcher ,
Sr. VP of Bus. Devel. & Strategic Planning
|Dr. Sudhir Agrawal D.Phil., F.R.S.C.,
Pres of Research and Director
|Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|